COR659 / Scripps Research Institute - LARVOL DELTA

Positive allosteric modulators of the GABAB receptor: a new class of ligands with therapeutic potential for alcohol use disorder. (PubMed, Alcohol Alcohol) - "These effects closely mirrored those of baclofen; notably, they were associated to remarkably lower levels of tolerance and toxicity. The recent transition of ASP8062 to clinical testing will soon prove whether these highly consistent preclinical data translate to AUD patients."

Journal • Addiction (Opioid and Alcohol)

Anorectic effect of COR659 in a rat model of overeating. (PubMed, Behav Pharmacol) - "Treatment with all 3 doses of COR659 produced a substantial decrease in intake of cookies and calories from cookies. These results extend the anorectic profile of COR659 to overconsumption of a highly palatable food and intake of large amounts of unnecessary calories."

Journal • Preclinical

Administration of the novel positive allosteric modulator of the GABAB receptor, COR659, effectively prevents binge-like alcohol drinking in rodents (Neuroscience 2022) - "COR659 administered intraperitoneally at the non-sedative doses of 10, 20, and 40 mg/kg, effectively prevented the intake of the excessive amount of alcohol promoted by exposing rodents to the abovementioned procedures. Overall, these data extend the anti-alcohol properties of COR659 to binge-like drinking in rodents and contribute to supporting the use of molecules belonging to the class of GABAB PAMs as a potential pharmacotherapy for AUD, including BD."

Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders